ICARE Newsletter Summer 2020

Treatment Advances Among Those with Von-Hippel Lindau (VHL) Disease

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below:

Von-Hippel Lindau (VHL) Disease: 

Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit from MK-6482, which subsequently led to the FDA breakthrough therapy designation for those with nonmetastatic RCC tumors < 3 cm in size.

Jonasch, et al. J Clin Oncol. 2020 May. Available at: https://tinyurl.com/jonasch2020

Permanent link to this article: https://inheritedcancer.net/9nls2020/